pharmaceuticals

Stefan Oelrich, Member of Bayer's Board of Management and Head of the Pharmaceuticals Division, is confident about the development pipeline. As one important patent expires, he points to a range of new products that will generate big sales.

Long-suffering Bayer shareholders are being asked to stump up 8 billion euros in a cash call. What looks like a bold move might just be courage born out of desperation.